You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

ALVAIZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Alvaiz, and when can generic versions of Alvaiz launch?

Alvaiz is a drug marketed by Teva Pharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ALVAIZ is eltrombopag choline. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag choline profile page.

DrugPatentWatch® Generic Entry Outlook for Alvaiz

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 5, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALVAIZ?
  • What are the global sales for ALVAIZ?
  • What is Average Wholesale Price for ALVAIZ?
Summary for ALVAIZ
International Patents:2
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for ALVAIZ
What excipients (inactive ingredients) are in ALVAIZ?ALVAIZ excipients list
DailyMed Link:ALVAIZ at DailyMed
Drug patent expirations by year for ALVAIZ
Drug Prices for ALVAIZ

See drug prices for ALVAIZ

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ALVAIZ
Generic Entry Date for ALVAIZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ALVAIZ

ALVAIZ is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALVAIZ is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ALVAIZ

Solid state forms of eltrombopag choline
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY

Solid state forms of eltrombopag choline
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

Solid state forms of eltrombopag choline
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Inc ALVAIZ eltrombopag choline TABLET;ORAL 216774-001 Nov 29, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Teva Pharms Inc ALVAIZ eltrombopag choline TABLET;ORAL 216774-003 Nov 29, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Teva Pharms Inc ALVAIZ eltrombopag choline TABLET;ORAL 216774-002 Nov 29, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Teva Pharms Inc ALVAIZ eltrombopag choline TABLET;ORAL 216774-004 Nov 29, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ALVAIZ

When does loss-of-exclusivity occur for ALVAIZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Patent: 92021
Patent: FORMES À L'ÉTAT SOLIDE D'ELTROMBOPAG CHOLINE (SOLID STATE FORMS OF ELTROMBOPAG CHOLINE)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ALVAIZ around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3692021 FORMES À L'ÉTAT SOLIDE D'ELTROMBOPAG CHOLINE (SOLID STATE FORMS OF ELTROMBOPAG CHOLINE) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2019071111 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ALVAIZ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1294378 C201000022 Spain ⤷  Sign Up PRODUCT NAME: ELTROMBOPAG; NATIONAL AUTHORISATION NUMBER: EU/1/10/612/001-006; DATE OF AUTHORISATION: 20100315; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/10/612/001-006; DATE OF FIRST AUTHORISATION IN EEA: 20100315
1294378 C300451 Netherlands ⤷  Sign Up PRODUCT NAME: ELTROMBOPAG, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/10/612/001-006 20100311
1534390 91 3-2010 Slovakia ⤷  Sign Up PRODUCT NAME: ELTROMBOPAG; REGISTRATION NO/DATE: EU/1/10/612/001 - EU/1/10/612/006 20100315
1294378 23/2010 Austria ⤷  Sign Up PRODUCT NAME: ELTROMBOPAG, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS UND SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/612/001-EU/1/10/612/006 (MITTEILUNG) 20100315
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.